SPRINGTIME FOR EUROPEAN BIOTECH?
Allergy firm Circassia raises $334M in new UK biotech IPO record
By Cormac Sheridan
Thursday, March 13, 2014
Circassia Pharmaceuticals plc created a new high-water mark for UK biotech by pricing its initial public offering (IPO) on the London Stock Exchange at £3.10 per share in a transaction that grossed £200 million (US$333.6 million).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.